Etropal ADXBUL:ETR 50 Market Cap is €12.60 Mil as of Jul. 12, 2026. GuruFocus rates XBUL:ETR with a GF Score™ of 50/100 and a GF Value™ of €8.59 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 866 Medical Devices & Instruments companies, Etropal AD ranks worse than 81.64% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Etropal AD's share price for the quarter that ended in Dec. 2025 was €4.5. Etropal AD's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 5.00 Mil. Therefore, Etropal AD's market cap for the quarter that ended in Dec. 2025 was €22.50 Mil.
Etropal AD's quarterly market cap
declined
from Dec. 2023 (€23.00 Mil) to Dec. 2024 (€21.50 Mil) but then
increased
from Dec. 2024 (€21.50 Mil) to Dec. 2025 (€22.50 Mil).
Etropal AD's annual market cap
declined
from Dec. 2023 (€23.00 Mil) to Dec. 2024 (€21.50 Mil) but then
increased
from Dec. 2024 (€21.50 Mil) to Dec. 2025 (€22.50 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Etropal AD's Enterprise Value for Today is €12.47 Mil.
Etropal AD (XBUL:ETR) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Etropal AD Market Cap Related Terms
Etropal AD Market Cap Historical Data
* Premium members only.
The historical data trend for Etropal AD's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBUL:ETR vs ISRG, BDX, MDLN: Market Cap Comparison
For the Medical Instruments & Supplies subindustry, Etropal AD's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Etropal AD Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Etropal AD's Market Cap distribution charts can be found below:
* The bar in red indicates where Etropal AD's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Etropal AD's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Etropal AD (XBUL:ETR) has a Market Cap of €12.60 Mil as of Jul. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Etropal AD and its competitors. According to the industry distribution chart, Etropal AD ranks #707 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 81.6%.
Is Etropal AD's Market Cap too high?
Etropal AD's current Market Cap is €12.60 Mil. Based on the distribution chart, Etropal AD ranks #707 out of 866 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Etropal AD has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Etropal AD's Market Cap compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Etropal AD ranks #707 out of 866 companies for Market Cap. This places Etropal AD in the lower half of its industry. The industry median Market Cap is 116.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 116.25, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Etropal AD and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 116.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Etropal AD's current Market Cap is €12.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Etropal AD stock overvalued right now?
Based on GuruFocus' analysis, Etropal AD (XBUL:ETR) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.59, compared to a current price of €2.52 — trading 70.7% below its estimated fair value. The current Market Cap is €12.60 Mil. Etropal AD's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Etropal AD (XBUL:ETR), the current Market Cap is €12.60 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Etropal AD (XBUL:ETR) Overvalued in 2026?
Based on GuruFocus' analysis, Etropal AD stock appears to be undervalued.
The current stock price of €2.52 is trading 70.7% below its estimated GF Value™ of €8.59.
GuruFocus considers Etropal AD to be Significantly Undervalued.
Key valuation signals for XBUL:ETR:
Market Cap: €12.60 Mil
GF Value™: €8.59 vs. price of €2.52 (70.7% below fair value)
No single metric tells the full story. See the XBUL:ETR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
50GF Score
Get the complete analysis for XBUL:ETR
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:ETR has been successfully added to your 
